BioWorld

Jan. 6, 2003

View Archived Issues

TolerRx Closes $35M Series C, Collaborates With Genentech

TolerRx Inc. is off and running, closing a $35 million Series C round and signing monoclonal antibody heavyweight Genentech Inc. to a co-development deal for TolerRx's lead product, TRX1. (BioWorld Today) Read More

Raven Raises $40M To Advance Monoclonal Antibody Programs

Read More

Endo Gains Rights To Pain Drugs Through Deal With SkyePharm

Read More

Genta Gets NDA Under Way For Intravenous Cancer Drug

Read More

Other News To Note

Read More

Appointments And Advancements

Read More